U.S. Markets close in 53 mins.

NanoViricides, Inc. (NNVC)


NYSE MKT - Nasdaq Real Time Price. Currency in USD
Add to watchlist
1.38-0.01 (-0.72%)
As of 3:06PM EDT. Market open.
People also watch
BTXISCOGALTECTEAVXL
Interactive chart
Previous Close1.39
Open1.41
Bid0.00 x
Ask0.00 x
Day's Range1.35 - 1.44
52 Week Range1.03 - 2.04
Volume89,255
Avg. Volume67,585
Market Cap86.69M
Beta0.26
PE Ratio (TTM)-6.90
EPS (TTM)-0.2
Earnings DateMay 12, 2017 - May 15, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
Trade prices are not sourced from all markets
  • Associated Press10 days ago

    NanoViricides reports 3Q loss

    On a per-share basis, the West Haven, Connecticut-based company said it had a loss of 5 cents. The company's shares closed at $1.24. A year ago, they were trading at $1.55. _____ This story was generated ...

  • NanoViricides Files Quarterly Report for Period Ending 2017-03-31
    PR Newswire10 days ago

    NanoViricides Files Quarterly Report for Period Ending 2017-03-31

    SHELTON, Conn., May 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed the quarterly report for its third quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Monday, May 15th. NanoViricides reported that it had approximately $16.74 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of March 31, 2017, the end of the reporting period. Briefly, holders of $5,000,000 principal value Series B Convertible Debentures, namely, an entity controlled by Dr. Milton Boniuk, a director of the Company, and The Boniuk Charitable Foundation, converted $5,000,000 of Series B debentures into equity, and the remaining $1,000,000 principal, with accrued interest as of the maturity date, was repaid to the holders thereof in cash, on or about.

  • NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles
    PR Newswirelast month

    NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

    SHELTON, Conn., April 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel. NanoViricides, Inc. is a global leader developing antiviral nanomedicines for the treatment of a number of different viral infections. The Company is currently focused on developing its broad spectrum anti-herpesvirus drug candidates.